BETTER BUILDINGS FOR BETTER PHARMACEUTICAL PRODUCTION

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.